News & Articles

The trial demonstrates that first-line pembrolizumab treatment improved overall and progression-free survival rates in patients with metastatic nonsquamous non-small cell lung cancer

The primary endpoint for first-line nivolumab-ipilimumab combo trial indicates improved progression-free survival in patients with advanced non-small cell lung cancer

Expansion of circulating tumor-specific T cells after nivolumab treatment suggests systemic antitumor immunity in patients with resectable lung cancer

The FT819 CAR T cell line has the potential to be mass-produced, stored, and made readily available for cancer immunotherapy

Crizotinib yielded a high objective response rate for adult patients with ALK-positive Inflammatory myofibroblastic tumor, and a 100 percent disease control rate

Research reveals that acquired HER2 mutations confer resistance to hormone therapy in ER-positive metastatic breast cancer